Brian Guan-Chyun Liu - 04 Jun 2026 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Reporting relationship: Director
Issuer ticker: CGON
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:30:19 UTC
Prior SEC filing: 15 Sep 2025
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Brian Guan-Chyun Liu

Key filing fact

Brian Guan-Chyun Liu filed Form 4 for CG Oncology, Inc. (CGON) on 05 Jun 2026.

Key facts

This page summarizes Brian Guan-Chyun Liu's Form 4 filing for CG Oncology, Inc. (CGON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002007835 Primary reporting owner

Liu Brian Guan-Chyun

Relationship: Director
Address: C/O CG ONCOLOGY, INC., 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS
Signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Brian Guan-Chyun Liu
Signature date: 05 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGON transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
Shares: +9,354
Change %
Price: $0.000000^*
Shares after: 9,354
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,354
Exercise price: $56.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.